Compare Fox Corp Class A (FOXA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Recursion Pharmaceuticals Inc — how do they compare? Fox Corp Class A trades at $62.88 (market cap $25.36B), while Recursion Pharmaceuticals Inc trades at $4.25 (market cap $2.14B). The key difference: Fox Corp Class A is far larger — about 11.9× Recursion Pharmaceuticals Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FOXA | RXRX | |
|---|---|---|
Market Cap | $25.36B | $2.14B |
Volume | 2,566,954 | 30,789,535 |
Sector | Media | Health |
52-Week High | $76.11 | $6.79 |
52-Week Low | $48.79 | $2.84 |
Typical Hold Time | 34 Days | 22 Days |
Enterprise Value | $28.72B | $1.66B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.42, up 1.15% with a bullish technical signal and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats and solid profitability metrics including 14.29% ROE and 9.84% net margin. Recent news highlights the pending Roku acquisition and regulatory scrutiny, while institutional activity shows CEO Lachlan Murdoch's significant $10.3 million share purchase in September 2026.
The outlook remains positive with a $72 consensus price target representing 13.5% upside potential. Key opportunities include continued earnings growth and strategic acquisitions, while risks center on regulatory approval for the Roku deal and potential market volatility. With no analyst sell ratings and strong institutional support, FOXA presents a compelling investment case in the media sector.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
